How the Drug Lobby Lost Its Mojo in Washington

How the Drug Lobby Lost Its Mojo in Washington

WASHINGTON– The drug market does not load the lobbying punch it as soon as did, and one sign is something unusual in the capital today– a dose of bipartisanship.

Sen. Chuck Grassley (R., Iowa) joined Sen. Ron Wyden (D., Ore.) to compose a costs last July to control prescription-drug costs, a concept the market has actually repressed given that the 1960 s. Sen. John Cornyn (R., Texas) with Sen. Richard Blumenthal (D., Conn.) sponsored an expense in May to block drug companies from utilizing patent laws to delay lower-priced drugs.

Read More